Table 1:

Patient Characteristics

	N (%)
Number Enrolled	39
Median age (IQR, range)	67 (8, 33–83)
Male	25 (64%)
Caucasian	38 (97%)
Median WBC (x10 3 ) (IQR, range)	3.6 (7.15, 0.4–59.7)
Secondary AML	19 (49%)
Prior MDS	16 (41%)
Prior CMML	2 (5%)
Prior MPN	1 (3%)
Therapy-related AML	3 (8%)
Cytogenetic Risk
High	13 (33%)
Intermediate	26 (67%)
Normal Karyotype	17 (44%)
ELN 2017 Risk Category
Favorable*	5 (13%)
Intermediate	9 (23%)
Adverse	25 (64%)
Mutation Profile
ASXL1	12 (31%)
DNMT3A	12 (31%)
RUNX1	8 (21%)
TET2	7 (18%)
NPM1	7 (18%)
SRSF2	7 (18%)
NRAS	6 (15%)
FLT3 ITD	5 (13%)
FLT3 TKD	3 (8%)
IDH1	5 (13%)
IDH2	5 (13%)
STAG2	5 (13%)
TP53	4 (10%)
PTPN11	4 (10%)
BCOR	4 (10%)
EZH2	4 (10%)
SF3B1	3 (8%)
BCORL1	3 (8%)
CEBPA	3 (8%)
CBL	3 (8%)
ZRSR2	1 (3%)
RIT1	1 (3%)
KRAS	1 (3%)
ETV6	1 (3%)
Other	7 (18%)

^*All favorable risk patients were 65 or older at the time of induction, and none had core binding factor-altered AML.